Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12325-013-0069-5 http://scihub22266oqcxt.onion/10.1007/s12325-013-0069-5 24249433/?report=reader!3898148!24249433     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Ther 2013 ; 30 (11): 945-66 Nephropedia Template TP {{tp|p=24249433|t=2013. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies |pdf=|usr=}}{{24249433}} gab.com Text Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies JO: Adv Ther http://www.kidney.de/pget.php?&tw=1&pmid=24249433 #FOAvip INTRODUCTION: Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms, effective management of related adverse events (AEs) is vital to ensure patient compliance and maximize clinical benefit with vandetanib therapy. METHODS: This expert meeting-based review aims to summarize published data on AEs associated with vandetanib therapy and to provide clinicians with specific practical guidance on education, monitoring, and management of toxicities induced in patients treated with vandetanib in advanced and metastatic MTC. The content of this review is based on the expert discussions from a multidisciplinary meeting held in October 2012. RESULTS: Characteristics, frequency, and risk data are outlined for a number of dermatological, cardiovascular, gastrointestinal, and general AEs related to vandetanib treatment. Preventive strategies, practical treatment suggestions, and points for clinical consideration are provided. CONCLUSIONS: Good patient and team communication is necessary for the prevention, early detection, and management of AEs of vandetanib. Physicians, nurses, and other healthcare providers play a critical role in providing AE management and patient support to optimize outcomes with vandetanib in MTC. Twit Text FOAVip Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies ????Adv Ther http://www.kidney.de/pget.php?&tw=1&pmid=24249433 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24249433 #FOAvip English Wikipedia <ref>{{Cite pmid|24249433}}</ref> Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies #MMPMID24249433 Grande E; Kreissl MC; Filetti S; Newbold K; Reinisch W; Robert C; Schlumberger M; Tolstrup LK; Zamorano JL; Capdevila J Adv Ther 2013[Nov]; 30 (11): 945-66 PMID24249433show ga INTRODUCTION: Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms, effective management of related adverse events (AEs) is vital to ensure patient compliance and maximize clinical benefit with vandetanib therapy. METHODS: This expert meeting-based review aims to summarize published data on AEs associated with vandetanib therapy and to provide clinicians with specific practical guidance on education, monitoring, and management of toxicities induced in patients treated with vandetanib in advanced and metastatic MTC. The content of this review is based on the expert discussions from a multidisciplinary meeting held in October 2012. RESULTS: Characteristics, frequency, and risk data are outlined for a number of dermatological, cardiovascular, gastrointestinal, and general AEs related to vandetanib treatment. Preventive strategies, practical treatment suggestions, and points for clinical consideration are provided. CONCLUSIONS: Good patient and team communication is necessary for the prevention, early detection, and management of AEs of vandetanib. Physicians, nurses, and other healthcare providers play a critical role in providing AE management and patient support to optimize outcomes with vandetanib in MTC. |Carcinoma, Neuroendocrine[MESH] |Cardiovascular Diseases/chemically induced/physiopathology/therapy[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Administration Schedule[MESH] |Drug Eruptions/etiology/physiopathology/therapy[MESH] |Drug-Related Side Effects and Adverse Reactions/radiotherapy/*therapy[MESH] |Female[MESH] |Gastrointestinal Diseases/chemically induced/physiopathology/therapy[MESH] |Humans[MESH] |Male[MESH] |Neoplasm Invasiveness/pathology[MESH] |Neoplasm Staging[MESH] |Patient Selection[MESH] |Piperidines/*adverse effects/therapeutic use[MESH] |Prognosis[MESH] |Quinazolines/*adverse effects/therapeutic use[MESH] |Risk Assessment[MESH] |Thyroid Neoplasms/*drug therapy/mortality/pathology[MESH]Vandetanib in advanced medullary thyroid cancer: review of adverse eve(epmc).pdf DeepDyve Pubget Overpricing